Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting - A quantitative coronary angiography and volumetric intravascular ultrasound study

Pi Ki Min, Jae Hun Jung, Young Guk Ko, Donghoon Choi, Yangsoo Jang, Mdwon Heum Shim

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: This study was designed to investigate the efficacy of cilostazol on the prevention of in-stent neointimal hyperplasia as measured by both quantitative coronary angiography (CAG) and volumetric intravascular ultrasound (IVUS). Methods and Results: Fifty-nine patients (39 men, age 62 years) undergoing elective coronary stenting were randomly assigned to receive aspirin plus Clopidogrel or ticlopidine (Group I, n=28, 30 lesions) or aspirin plus clopidogrel or ticlopidine plus cilostazol (Group II, n=31, 35 lesions). CAG and IVUS were performed and repeated at 6 months to assess the primary endpoints of minimal luminal diameter (MLD) and in-stent neointimal hyperplasia volume. Follow-up CAG was performed on all patients and follow-up IVUS study was available for 50 lesions in 48 patients (24 lesions in Group I, 26 in Group II). There were no significant differences in the baseline angiographic data between the 2 groups. At 6 months follow-up, in-stent MLD was 1.90±0.76 mm in Group I and 2.41±0.85 mm in Group II (p=0.006). Volumetric IVUS at 6 months demonstrated that in-stent intimal hyperplasia volume per stent length was 2.2±1.4 mm3/mm in Group I and 1.0±0.5mm 3/mm in Group II (p=0.001). Conclusions: Triple antiplatelet therapy including cilostazol seems to be more effective at preventing in-stent neointimal hyperplasia than a dual antiplatelet regimen.

Original languageEnglish
Pages (from-to)1685-1690
Number of pages6
JournalCirculation Journal
Volume71
Issue number11
DOIs
Publication statusPublished - 2007 Dec 17

Fingerprint

Coronary Angiography
Hyperplasia
Stents
Coronary Vessels
clopidogrel
Ticlopidine
Aspirin
Tunica Intima
cilostazol

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

@article{e73505b9407044c4a0a765c31e45728b,
title = "Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting - A quantitative coronary angiography and volumetric intravascular ultrasound study",
abstract = "Background: This study was designed to investigate the efficacy of cilostazol on the prevention of in-stent neointimal hyperplasia as measured by both quantitative coronary angiography (CAG) and volumetric intravascular ultrasound (IVUS). Methods and Results: Fifty-nine patients (39 men, age 62 years) undergoing elective coronary stenting were randomly assigned to receive aspirin plus Clopidogrel or ticlopidine (Group I, n=28, 30 lesions) or aspirin plus clopidogrel or ticlopidine plus cilostazol (Group II, n=31, 35 lesions). CAG and IVUS were performed and repeated at 6 months to assess the primary endpoints of minimal luminal diameter (MLD) and in-stent neointimal hyperplasia volume. Follow-up CAG was performed on all patients and follow-up IVUS study was available for 50 lesions in 48 patients (24 lesions in Group I, 26 in Group II). There were no significant differences in the baseline angiographic data between the 2 groups. At 6 months follow-up, in-stent MLD was 1.90±0.76 mm in Group I and 2.41±0.85 mm in Group II (p=0.006). Volumetric IVUS at 6 months demonstrated that in-stent intimal hyperplasia volume per stent length was 2.2±1.4 mm3/mm in Group I and 1.0±0.5mm 3/mm in Group II (p=0.001). Conclusions: Triple antiplatelet therapy including cilostazol seems to be more effective at preventing in-stent neointimal hyperplasia than a dual antiplatelet regimen.",
author = "Min, {Pi Ki} and Jung, {Jae Hun} and Ko, {Young Guk} and Donghoon Choi and Yangsoo Jang and Shim, {Mdwon Heum}",
year = "2007",
month = "12",
day = "17",
doi = "10.1253/circj.71.1685",
language = "English",
volume = "71",
pages = "1685--1690",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "11",

}

Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting - A quantitative coronary angiography and volumetric intravascular ultrasound study. / Min, Pi Ki; Jung, Jae Hun; Ko, Young Guk; Choi, Donghoon; Jang, Yangsoo; Shim, Mdwon Heum.

In: Circulation Journal, Vol. 71, No. 11, 17.12.2007, p. 1685-1690.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting - A quantitative coronary angiography and volumetric intravascular ultrasound study

AU - Min, Pi Ki

AU - Jung, Jae Hun

AU - Ko, Young Guk

AU - Choi, Donghoon

AU - Jang, Yangsoo

AU - Shim, Mdwon Heum

PY - 2007/12/17

Y1 - 2007/12/17

N2 - Background: This study was designed to investigate the efficacy of cilostazol on the prevention of in-stent neointimal hyperplasia as measured by both quantitative coronary angiography (CAG) and volumetric intravascular ultrasound (IVUS). Methods and Results: Fifty-nine patients (39 men, age 62 years) undergoing elective coronary stenting were randomly assigned to receive aspirin plus Clopidogrel or ticlopidine (Group I, n=28, 30 lesions) or aspirin plus clopidogrel or ticlopidine plus cilostazol (Group II, n=31, 35 lesions). CAG and IVUS were performed and repeated at 6 months to assess the primary endpoints of minimal luminal diameter (MLD) and in-stent neointimal hyperplasia volume. Follow-up CAG was performed on all patients and follow-up IVUS study was available for 50 lesions in 48 patients (24 lesions in Group I, 26 in Group II). There were no significant differences in the baseline angiographic data between the 2 groups. At 6 months follow-up, in-stent MLD was 1.90±0.76 mm in Group I and 2.41±0.85 mm in Group II (p=0.006). Volumetric IVUS at 6 months demonstrated that in-stent intimal hyperplasia volume per stent length was 2.2±1.4 mm3/mm in Group I and 1.0±0.5mm 3/mm in Group II (p=0.001). Conclusions: Triple antiplatelet therapy including cilostazol seems to be more effective at preventing in-stent neointimal hyperplasia than a dual antiplatelet regimen.

AB - Background: This study was designed to investigate the efficacy of cilostazol on the prevention of in-stent neointimal hyperplasia as measured by both quantitative coronary angiography (CAG) and volumetric intravascular ultrasound (IVUS). Methods and Results: Fifty-nine patients (39 men, age 62 years) undergoing elective coronary stenting were randomly assigned to receive aspirin plus Clopidogrel or ticlopidine (Group I, n=28, 30 lesions) or aspirin plus clopidogrel or ticlopidine plus cilostazol (Group II, n=31, 35 lesions). CAG and IVUS were performed and repeated at 6 months to assess the primary endpoints of minimal luminal diameter (MLD) and in-stent neointimal hyperplasia volume. Follow-up CAG was performed on all patients and follow-up IVUS study was available for 50 lesions in 48 patients (24 lesions in Group I, 26 in Group II). There were no significant differences in the baseline angiographic data between the 2 groups. At 6 months follow-up, in-stent MLD was 1.90±0.76 mm in Group I and 2.41±0.85 mm in Group II (p=0.006). Volumetric IVUS at 6 months demonstrated that in-stent intimal hyperplasia volume per stent length was 2.2±1.4 mm3/mm in Group I and 1.0±0.5mm 3/mm in Group II (p=0.001). Conclusions: Triple antiplatelet therapy including cilostazol seems to be more effective at preventing in-stent neointimal hyperplasia than a dual antiplatelet regimen.

UR - http://www.scopus.com/inward/record.url?scp=36949002072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36949002072&partnerID=8YFLogxK

U2 - 10.1253/circj.71.1685

DO - 10.1253/circj.71.1685

M3 - Article

C2 - 17965485

AN - SCOPUS:36949002072

VL - 71

SP - 1685

EP - 1690

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 11

ER -